Ralliant (NYSE:RAL) Coverage Initiated at Evercore

Evercore assumed coverage on shares of Ralliant (NYSE:RAL) in a research note issued on Tuesday. The brokerage set an “outperform” rating and a $80.00 price target on the stock. Evercore’s target price suggests a potential upside of 25.38% from the stock’s current price.

Several other research analysts have also recently weighed in on RAL. TD Cowen boosted their price target on shares of Ralliant from $55.00 to $70.00 and gave the company a “buy” rating in a research report on Wednesday, May 20th. Zacks Research upgraded shares of Ralliant from a “strong sell” rating to a “hold” rating in a research report on Monday, April 13th. Wall Street Zen lowered shares of Ralliant from a “buy” rating to a “hold” rating in a report on Sunday, May 31st. Oppenheimer increased their price target on shares of Ralliant from $50.00 to $65.00 and gave the company an “outperform” rating in a research note on Wednesday, May 13th. Finally, Citigroup raised their price target on shares of Ralliant from $51.00 to $70.00 and gave the stock a “buy” rating in a report on Wednesday, May 13th. Seven equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $67.30.

Ralliant Price Performance

Shares of RAL stock traded up $2.78 during trading hours on Tuesday, reaching $63.81. The company had a trading volume of 59,398 shares, compared to its average volume of 1,681,750. Ralliant has a 12-month low of $37.27 and a 12-month high of $64.04. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.05 and a current ratio of 1.61. The company has a market capitalization of $7.14 billion and a price-to-earnings ratio of -5.82. The stock has a fifty day moving average of $51.16 and a 200-day moving average of $49.32.

Ralliant (NYSE:RAL) last announced its quarterly earnings data on Tuesday, May 12th. The company reported $0.57 EPS for the quarter, topping analysts’ consensus estimates of $0.49 by $0.08. The firm had revenue of $534.60 million for the quarter. Ralliant had a positive return on equity of 12.49% and a negative net margin of 58.55%.The company’s revenue for the quarter was up 11.0% compared to the same quarter last year. Ralliant has set its FY 2026 guidance at 2.530-2.690 EPS and its Q2 2026 guidance at 0.580-0.640 EPS. On average, equities analysts anticipate that Ralliant will post 2.64 earnings per share for the current year.

Institutional Investors Weigh In On Ralliant

Institutional investors and hedge funds have recently modified their holdings of the company. First Nebraska Trust Co acquired a new position in shares of Ralliant in the first quarter valued at approximately $435,000. Irenic Capital Management LP lifted its holdings in Ralliant by 424.1% during the 1st quarter. Irenic Capital Management LP now owns 1,740,218 shares of the company’s stock worth $72,376,000 after buying an additional 1,408,176 shares in the last quarter. Amundi boosted its position in Ralliant by 6.2% in the 1st quarter. Amundi now owns 148,614 shares of the company’s stock valued at $6,181,000 after buying an additional 8,649 shares during the period. California State Teachers Retirement System grew its stake in shares of Ralliant by 23.1% in the first quarter. California State Teachers Retirement System now owns 130,822 shares of the company’s stock worth $5,441,000 after acquiring an additional 24,591 shares in the last quarter. Finally, Royal Bank of Canada grew its stake in shares of Ralliant by 175.7% in the first quarter. Royal Bank of Canada now owns 50,251 shares of the company’s stock worth $2,091,000 after acquiring an additional 32,024 shares in the last quarter.

About Ralliant

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.